Despite the availability of a series of classical antibiotic drugs, bacterial infections continue to represent a significant and urgent threat to global human health. The emergence of drug-resistant bacteria and the slow pace of antibiotic development have rendered current treatment methods inadequate in meeting the clinical demands of bacterial infections. Consequently, there is an increasingly urgent and vital need for the development of safe, efficient, and alternative novel antimicrobial agents in the medical and healthcare field. Over the past five years, there has been a notable expansion in the field of nanomedicine with regard to the prevention and control of infectious diseases. The objective of this article is to provide a comprehensive review of the latest research developments in the field of metal nanomaterials for medical antimicrobial therapy. We begin by delineating the gravity of the bacterial infection crisis, subsequently undertaking a comprehensive examination of the potential mechanisms through which nanoparticles may combat bacterial infections and the specific applications of these nanomaterials in the treatment of diverse infectious diseases. In conclusion, we eagerly anticipate the future development directions of metal nanomaterials in the field of antimicrobial therapy. We believe that with continuous technological advancements and innovations, this field will make even more outstanding contributions to safeguarding human health and well-being.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892188PMC
http://dx.doi.org/10.1186/s12951-025-03249-6DOI Listing

Publication Analysis

Top Keywords

bacterial infections
12
human health
8
infectious diseases
8
metal nanomaterials
8
antimicrobial therapy
8
field
5
advances challenges
4
challenges metal-based
4
antimicrobial
4
metal-based antimicrobial
4

Similar Publications

Background: Infection is a leading cause of death after pediatric heart transplants (PHTs). Understanding of common pathogens is needed to guide testing strategies and empiric antibiotic use.

Methods: We conducted a 3-center retrospective study of PHT recipients ≤18 years old presenting to cardiology clinics or emergency departments (EDs) from 2010 to 2018 for evaluation of suspected infections within 2 years of transplant.

View Article and Find Full Text PDF

Febrile infants 8-60 days of age underwent multiplex polymerase chain reaction (mPCR) testing in the emergency department. The virus-positive rate was 61.3%, with serious bacterial infections (SBIs) at 12.

View Article and Find Full Text PDF

Background: Hospital studies suggest that scrub typhus is a leading cause of severe undifferentiated fever in regions across Asia where the disease is endemic, but the population-based incidence of infection and illness has been little studied.

Methods: We conducted a population-based cohort study to assess epidemiologic and clinical characteristics of scrub typhus in 37 villages in Tamil Nadu, India, where the disease is highly endemic. Study participants were visited every 6 to 8 weeks over a period of 2 years; a venous blood sample was obtained from those who had had fever since the last visit.

View Article and Find Full Text PDF

Infected bone defects show a significant reduction in neovascularization during the healing process, primarily due to persistent bacterial infection and immune microenvironmental disorders. Existing treatments are difficult to simultaneously meet the requirements of antibacterial and anti-inflammatory treatments for infected bone defects, which is a key clinical therapeutic challenge that needs to be addressed. In this study, a conductive hydrogel based on copper nanoparticles was developed for controlling bacterial infection and remodeling the immune microenvironment.

View Article and Find Full Text PDF

Mucormycosis is a fungal infection caused by Mucorales fungi that cause severe disease and fatality, especially in immunocompromised individuals. Although vaccines and immunotherapeutics have been successful in combating viral and bacterial infections, approved antifungal immunotherapies are yet to be realized. To address this gap, monoclonal antibodies targeting invasive fungal infections have emerged as a promising approach, particularly for immunocompromised patients who are unlikely to maximally benefit from vaccines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!